No description available.

In dieser Arbeit werden Möglichkeiten zur Homogenisierung von Widerstandsprofilen entlang von phosphordotierten, gerichtet erstarrten, multikristallinen Silizium (mc-Si) Blöcken für PV-Anwendungen untersucht. Die im Rahmen der Dissertation durchgeführte analytische Untersuchung konzentriert sich auf den Phosphortransport in der Siliziumschmelze, an der Grenzfläche zwischen Kristall und Schmelze, an der Schmelzenoberfläche und in der Gasphase oberhalb der Schmelze. Es wurden drei Prozessparameter identifiziert, die den stärksten Einfluss auf die Phosphorverteilung in multikristallinen Blöcken haben: die Durchmischung der Schmelze, der Gesamtgasdruck in der Anlage und der Gasfluss über der Schmelze. Variationen in der Stärke der TMF sind sinnvoll, um die Phosphorverteilung entlang der Barrenhöhe zu beeinflussen. Ein schwaches TMF bewirkt eine gleichmäßigere Dotierstoffverteilung und führt zu einem verringerten spezifischen Widerstand des Blocks in den Anfangsstadien der Kristallisation, während ein starkes TMF einen signifikanten Effekt auf die Phosphorverdampfung hat und zu einem Anstieg des spezifischen Widerstandes zum Ende des Blocks hin führt. Die Ergebnisse der Experimente zeigten, dass die Verringerung des Gasdrucks zu einer deutlich verstärkten Phosphorverdampfung von der freien Schmelzenoberfläche führt und damit den spezifischen Widerstand des erstarrten Blocks erhöht, vor allem gegen dessen Ende hin. Die während der Studie gewonnenen Erkenntnisse wurden für die Optimierung der typischen G1-Wachstumsrezeptur verwendet. Die mit diesem Rezept gezüchteten G1 mc-Si Blöcke zeigen eine gleichmäßigere Widerstandsverteilung als solche, die mit einem typischen Rezept gezüchtet wurden. Die Widerstandsvariation wurde auf 55 % verringert und erfüllte den von der Marktspezifikation vorgegebenen Zielbereich von 3,0 - 1,0 Ω·cm. Die entwickelte Rezeptur wurde erfolgreich für die gerichtete Erstarrung mit Keimvorgabe übertragen. / The research described in this thesis is focused on homogenization of resistivity profiles along phosphorus-doped directionally solidified multicrystalline silicon (mc-Si) ingots for PV application. The analytical study conducted within the framework of the thesis is focused on phosphorus transport in the silicon melt, at the crystal-melt interface, at the melt surface and in the gaseous phase above the melt. Three process parameters were identified to have the most dominant influence on phosphorus distribution in multicrystalline ingots: melt mixing, furnace ambient gas pressure and gas flow above the melt. It was found that variations in strength of TMF could be used to control the phosphorus distribution along the ingot’s length. Weak TMF provokes more uniform dopant distribution and results in decreased ingot resistivity at the initial stages of crystallization, while strong TMF has more prominent effect on phosphorus evaporation that leads to the increase of resistivity towards the ingot’s end. The results of experiments demonstrated that reduction of ambient gas pressure leads to significantly intensified phosphorus evaporation from the free melt surface and increases the resistivity of the solidified ingot, especially towards its end. The findings obtained during the study were used for the adjustment of the typical G1 growth recipe. Conventional G1 mc-Si ingots grown using this recipe show more uniform resistivity distribution than those grown using a typical one. Resistivity variation was reduced to 55% and met the target range of 3.0 – 1.0 Ω·cm set by market specification. The developed recipe was successfully replicated for directional solidification seeded growth.

Melt flow plays an important role in directional solidification of multicrystalline silicon influencing the temperature field and the crystallization interface as well as the transport of impurities. This work investigates the potential of a traveling magnetic field (TMF) for an active control of the melt flow. A system of 3D numerical models was developed and adapted based on open-source software for calculations of Lorentz force, melt flow, and related phenomena. Isothermal and non-isothermal model experiments with a square GaInSn melt were used to validate the numerical models by direct velocity measurements. Several new 3D flow structures of turbulent TMF flows were observed for different melt heights. Further numerical parameter studies carried out for silicon melts showed that already a weak TMF-induced Lorentz force can stir impurities near to the complete mixing limit. Simultaneously, the deformed temperature field leads to an increase of the deflection of crystallization interface, which may exhibit a distinct asymmetry. The numerical results of this work were implemented in a research-scale silicon crystallization furnace. Scaling laws for various phenomena were derived allowing a limited transfer of the results to the industrial scale.

Site-specific tyrosine-type recombinases are effective tools for genome engineering, with the first engineered variants having demonstrated therapeutic potential. So far, adaptation to new DNA target site selectivity of designer-recombinases has been achieved mostly through iterative cycles of directed molecular evolution. While effective, directed molecular evolution methods are laborious and time consuming. To accelerate the development of designer-recombinases I evaluated two sequencing approaches and gathered the sequence information of over two million Cre-like recombinase sequences evolved for 89 different target sites. With this information I first investigated the sequence compositions and residue changes of the recombinases to further our understanding of their target site selectivity. The complexity of the data led me to a generative deep learning approach. Using the sequence data I trained a conditional variational autoencoder called RecGen (Recombinase Generator) that is capable of generating novel recombinases for a given target site. With computational evaluation of the sequences I revealed that known recombinases functional on the desired target site are generally more similar to the RecGen predicted recombinases than other recombinase libraries. Additionally, I could experimentally show that predicted recombinases for known target sites are at least as active as the evolved recombinases. Finally, I also experimentally show that 4 out of 10 recombinases predicted for novel target sites are capable of excising their respective target sites. As a bonus to RecGen I also developed a new method capable of accurate sequencing of recombinases with nanopore sequencing while simultaneously counting DNA editing events. The data of this method should enable the next development iteration of RecGen.

Background Growing evidence emphasizes the relevance of sphingolipids for metabolism and immunity of antigen-presenting cells (APC). APCs are key players in balancing tolerogenic and encephalitogenic responses in immunology. In contrast to the well-known prominent effects of sphingosine-1-phosphate (S1P) on lymphocyte trafficking, modulatory effects on APCs have not been fully characterized. Methods Frequencies and activation profiles of dendritic cell (DC) subtypes, monocytes, and T cell subsets in 35 multiple sclerosis (MS) patients were evaluated prior and after undergoing fingolimod treatment for up to 24 months. Impact of fingolimod and S1P on maturation and activation profile, pro-inflammatory cytokine release, and phagocytotic capacity was assessed in vitro and ex vivo. Modulation of DC-dependent programming of naïve CD4+ T cells, as well as CD4+ and CD8+ T cell proliferation, was also investigated in vitro and ex vivo. Results Fingolimod increased peripheral slanDC count—CD1+ DC, and monocyte frequencies remained stable. While CD4+ T cell count decreased, ratio of Treg/Th17 significantly increased in fingolimod-treated patients over time. CD83, CD150, and HLADR were all inhibited, but CD86 was upregulated in DCs after incubation in the presence of fingolimod. Fingolimod but not S1P was associated with reduced release of pro-inflammatory cytokines from DCs and monocytes in vitro and ex vivo. Fingolimod also inhibited phagocytic capacity of slanDCs and monocytes. After fingolimod, slanDCs demonstrated reduced potential to induce interferon–gamma-expressing Th1 or IL-17-expressing Th17 cells and DC-dependent T cell proliferation in vitro and in fingolimod-treated patients. Conclusions We present the first evidence that S1P-directed therapies can act additionally as immunomodulators that decrease the pro-inflammatory capabilities of APCs, which is a crucial element in DC-dependent T cell activation and programming.

Background Growing evidence emphasizes the relevance of sphingolipids for metabolism and immunity of antigen-presenting cells (APC). APCs are key players in balancing tolerogenic and encephalitogenic responses in immunology. In contrast to the well-known prominent effects of sphingosine-1-phosphate (S1P) on lymphocyte trafficking, modulatory effects on APCs have not been fully characterized. Methods Frequencies and activation profiles of dendritic cell (DC) subtypes, monocytes, and T cell subsets in 35 multiple sclerosis (MS) patients were evaluated prior and after undergoing fingolimod treatment for up to 24 months. Impact of fingolimod and S1P on maturation and activation profile, pro-inflammatory cytokine release, and phagocytotic capacity was assessed in vitro and ex vivo. Modulation of DC-dependent programming of naïve CD4+ T cells, as well as CD4+ and CD8+ T cell proliferation, was also investigated in vitro and ex vivo. Results Fingolimod increased peripheral slanDC count—CD1+ DC, and monocyte frequencies remained stable. While CD4+ T cell count decreased, ratio of Treg/Th17 significantly increased in fingolimod-treated patients over time. CD83, CD150, and HLADR were all inhibited, but CD86 was upregulated in DCs after incubation in the presence of fingolimod. Fingolimod but not S1P was associated with reduced release of pro-inflammatory cytokines from DCs and monocytes in vitro and ex vivo. Fingolimod also inhibited phagocytic capacity of slanDCs and monocytes. After fingolimod, slanDCs demonstrated reduced potential to induce interferon–gamma-expressing Th1 or IL-17-expressing Th17 cells and DC-dependent T cell proliferation in vitro and in fingolimod-treated patients. Conclusions We present the first evidence that S1P-directed therapies can act additionally as immunomodulators that decrease the pro-inflammatory capabilities of APCs, which is a crucial element in DC-dependent T cell activation and programming.

No description available.